MCID: CRH001
MIFTS: 74

Crohn's Disease

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Crohn's Disease

MalaCards integrated aliases for Crohn's Disease:

Name: Crohn's Disease 11 42 75 41 14 36 16 33
Crohn Disease 11 42 5 14 71 33
Regional Enteritis 75 5 71 33
Pediatric Crohn's Disease 11 19 71
Crohn's Disease of Large Bowel 11 71
Epidemic Viral Gastroenteritis Due to Norwalk Virus 33
Intestinal Ulcer and Erosion Due to Crohn Disease 33
Acute Gastroenteropathy Due to Norwalk Agent 33
Viral Gastroenteritis Due to Norwalk Agent 33
Small Round Structured Virus Enteritis 33
Cobble-Stone Appearance of Intestine 33
Epidemic Winter Vomiting Disease 33
Regional Enteritis of Bowel 33
Epidemic Vomiting Syndrome 33
Crohn's Regional Enteritis 33
Crohn's Disease of Colon 11
Enteritis, Granulomatous 42
Granulomatous Enteritis 33
Colitis, Granulomatous 42
Cd - [crohn's Disease] 33
Granulomatous Colitis 11
Adenoviral Enteritis 33
Enteritis, Regional 42
Noroviral Enteritis 33
Crohn's Enteritis 42
Epidemic Vomiting 33
Crohn Disease Nos 33
Winter Vomiting 33
Epidemic Nausea 33
Enteritis 71
Ileitis 71
Crohns 33

Classifications:



External Ids:

Disease Ontology 11 DOID:8778
ICD9CM 34 555.1
MeSH 43 D003424
NCIt 49 C37262
SNOMED-CT 68 7620006
UMLS 71 C0010346 C0014335 C0020877 more

Summaries for Crohn's Disease

MedlinePlus: 41 What is Crohn's disease? Crohn's disease is a chronic disease that causes inflammation in your digestive tract. It can affect any part of your digestive tract, which runs from your mouth to your anus. But it usually affects your small intestine and the beginning of your large intestine. Crohn's disease is an inflammatory bowel disease (IBD). Ulcerative colitis and microscopic colitis are other common types of IBD. What causes Crohn's disease? The cause of Crohn's disease is unknown. Researchers think that an autoimmune reaction may be one cause. An autoimmune reaction happens when your immune system attacks healthy cells in your body. Genetics may also play a role, since Crohn's disease can run in families. Stress and eating certain foods don't cause the disease, but they can make your symptoms worse. Who is at risk for Crohn's disease? There are certain factors which can raise your risk of Crohn's disease: Family history of the disease. Having a parent, child, or sibling with the disease puts you at higher risk. Smoking. This may double your risk of developing Crohn's disease. Certain medicines, such as antibiotics, birth-control pills, and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen. These may slightly increase your chance of developing Crohn's. A high-fat diet. This may also slightly increase your risk of Crohn's. What are the symptoms of Crohn's disease? The symptoms of Crohn's disease can vary, depending where and how severe your inflammation is. The most common symptoms include: Diarrhea Cramping and pain in your abdomen Weight loss Some other possible symptoms are: Anemia, a condition in which you have fewer red blood cells than normal Eye redness or pain Fatigue Fever Joint pain or soreness Nausea or loss of appetite Skin changes that involve red, tender bumps under the skin Stress and eating certain foods such as carbonated drinks and high-fiber foods may make some people's symptoms worse. What other problems can Crohn's disease cause? Crohn's disease can cause other problems, including: Intestinal obstruction, a blockage in the intestine Fistulas, abnormal connections between two parts inside of the body Abscesses, pus-filled pockets of infection Anal fissures, small tears in your anus that may cause itching, pain, or bleeding Ulcers, open sores in your mouth, intestines, anus, or perineum Malnutrition, when your body does not get the right amount of vitamins, minerals, and nutrients it needs Inflammation in other areas of your body, such as your joints, eyes, and skin How is Crohn's disease diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A family history A physical exam, including Checking for bloating in your abdomen Listening to sounds within your abdomen using a stethoscope Tapping on your abdomen to check for tenderness and pain and to see if your liver or spleen is abnormal or enlarged Various tests, including Blood and stool tests A colonoscopy An upper GI endoscopy, a procedure in which your provider uses a scope to look inside your mouth, esophagus, stomach, and small intestine Diagnostic imaging tests, such as a CT scan or an upper GI series. An upper GI series uses a special liquid called barium and x-rays. Drinking the barium will make your upper GI tract more visible on an x-ray. What are the treatments for Crohn's disease? There is no cure for Crohn's disease, but treatments can decrease the inflammation in your intestines, relieve symptoms, and prevent complications. Treatments include medicines, bowel rest, and surgery. No single treatment works for everyone. You and your health care provider can work together to figure out which treatment is best for you: Medicines for Crohn's include various medicines that decrease the inflammation. Some of these medicines do this by reducing the activity of your immune system. Medicines can also help with symptoms or complications, such as nonsteroidal anti-inflammatory drugs and anti-diarrheal medicines. If your Crohn's causes an infection, you may need antibiotics. Bowel rest involves drinking only certain liquids or not eating or drinking anything. This allows your intestines to rest. You may need to do this if your Crohn's disease symptoms are severe. You get your nutrients through drinking a liquid, a feeding tube, or an intravenous (IV) tube. You may need to do bowel rest in the hospital, or you may be able to do it at home. It will last for a few days or up to several weeks. Surgery can treat complications and reduce symptoms when other treatments are not helping enough. The surgery will involve removing a damaged part of your digestive tract to treat Fistulas Bleeding that is life threatening Intestinal obstructions Side effects from medicines when they threaten your health Symptoms when medicines do not improve your condition Changing your diet can help reduce symptoms. Your provider may recommend that you make changes to your diet, such as: Avoiding carbonated drinks Avoiding popcorn, vegetable skins, nuts, and other high-fiber foods Drinking more liquids Eating smaller meals more often Keeping a food diary to help identify foods that cause problems Some people also need go on special diet, such as a low-fiber diet. National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Crohn's Disease, also known as crohn disease, is related to inflammatory bowel disease and ulcerative colitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Crohn's Disease is IRGM (Immunity Related GTPase M), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Hydrocortisone succinate and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are homeostasis/metabolism and cardiovascular system

MedlinePlus Genetics: 42 Crohn disease is a complex, long-lasting (chronic) disorder that primarily affects the digestive system. This condition involves an abnormal immune response that causes excess inflammation. It most often affects the intestinal walls, particularly in the lower part of the small intestine (the ileum) and portions of the large intestine (the colon). However, inflammation can occur in any part of the digestive system, from the mouth to the anus. The inflamed tissues become thick and swollen, and the inner surfaces of the digestive system may develop open sores (ulcers).Crohn disease most commonly appears in a person's late teens or twenties, although the disease can begin at any age. Signs and symptoms tend to flare up multiple times throughout life. The most common features of this condition are persistent diarrhea, abdominal pain and cramping, loss of appetite, weight loss, and fever. Some people with Crohn disease have blood in the stool from inflamed tissues in the intestine; over time, chronic bleeding can lead to a low number of red blood cells (anemia). In some cases, Crohn disease can also cause inflammation affecting the joints, eyes, or skin.Intestinal blockage is a common complication of Crohn disease. Blockages are caused by swelling or a buildup of scar tissue in the intestinal walls. Some affected individuals also develop fistulae, which are abnormal connections between the intestine and other tissues. Fistulae occur when ulcers break through the intestinal wall and passages form between loops of the intestine or between the intestine and nearby structures (such as the bladder, vagina, or skin).Crohn disease is one common form of inflammatory bowel disease (IBD). Another type of IBD, ulcerative colitis, also causes chronic inflammation of the intestinal lining. Unlike Crohn disease, which can affect any part of the digestive system, ulcerative colitis typically causes inflammation only in the colon.

Disease Ontology: 11 An intestinal disease that involves inflammation located in intestine.

Wikipedia: 75 Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the... more...

Related Diseases for Crohn's Disease

Diseases related to Crohn's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1718)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 32.6 S100A9 S100A8 S100A12 LACC1 ITGA4 IRGM
2 ulcerative colitis 32.6 S100A12 LACC1 IRGM CCR6
3 colitis 32.4 S100A12 LACC1 IRGM CCR6
4 crohn's colitis 31.8 IRGM CCR6
5 psoriasis 31.4 S100A9 S100A8 S100A12 ITGA4 CCR6 ADAM17
6 inflammatory bowel disease 5 31.4 IRGM IL18RAP CCR6
7 takayasu arteritis 31.4 S100A12 IL12RB2 HP
8 sarcoidosis 1 31.3 S100A9 IL12RB2 CCR6
9 juvenile rheumatoid arthritis 31.1 S100A9 S100A8 HP CCR6
10 rheumatoid arthritis 31.1 S100A9 S100A8 S100A12 ITGA4 IL26 IL18BP
11 leprosy 3 31.0 LACC1 IRGM CCR6
12 spondylarthropathy 30.9 S100A9 S100A8 HP
13 cystic fibrosis 30.8 S100A9 S100A8 S100A12 HP CEACAM6 ADAM17
14 lung disease 30.7 S100A9 S100A8 CCR6 ADAM17
15 inflammatory bowel disease 23 30.6 IL12RB2 CCR6
16 inflammatory bowel disease 18 30.4 CCR6 ADAM17
17 peptic esophagitis 30.4 S100A8 CCR6
18 autoimmune gastritis 29.9 S100A8 CCR6
19 gastric lymphoma 29.7 S100A8 CCR6
20 crohn's disease of the esophagus 11.5
21 gastroduodenal crohn's disease 11.4
22 inflammatory bowel disease 1 11.4
23 ileitis 11.3
24 melkersson-rosenthal syndrome 11.3
25 diarrhea 11.2
26 colorectal cancer 11.2
27 inflammatory bowel disease 29 11.2
28 inflammatory bowel disease 31, autosomal recessive 11.2
29 ileocolitis 11.2
30 bowel dysfunction 11.2
31 pyoderma gangrenosum 11.2
32 rickets 11.2
33 inflammatory bowel disease 13 11.1
34 inflammatory bowel disease 14 11.1
35 inflammatory bowel disease 25, autosomal recessive 11.1
36 immunodeficiency 89 and autoimmunity 11.1
37 skin tag 11.1
38 orofacial granulomatosis 11.1
39 granulomatous disease, chronic, x-linked 11.1
40 hermansky-pudlak syndrome 5 11.1
41 hermansky-pudlak syndrome 7 11.1
42 hermansky-pudlak syndrome due to bloc-2 deficiency 11.1
43 hermansky-pudlak syndrome due to bloc-3 deficiency 11.1
44 keratomalacia 11.1
45 hemorrhoid 11.1
46 epidermolysis bullosa acquisita 11.1
47 lymphoproliferative syndrome, x-linked, 2 11.0
48 stomach disease 11.0
49 anal canal squamous cell carcinoma 11.0
50 rectosigmoid junction neoplasm 11.0

Comorbidity relations with Crohn's Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Inflammatory Bowel Disease 1
Intestinal Obstruction Protein-Energy Malnutrition
Ulcerative Colitis

Graphical network of the top 20 diseases related to Crohn's Disease:



Diseases related to Crohn's Disease

Symptoms & Phenotypes for Crohn's Disease

UMLS symptoms related to Crohn's Disease:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Crohn's Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ADAM17 CCR6 CEACAM6 CEP43 FMNL2 HP
2 no effect GR00402-S-2 10.17 CCR6 CEACAM6 CEP43 FMNL2 HP HSPA2

MGI Mouse Phenotypes related to Crohn's Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ADAM17 CCR6 CEACAM6 CEP43 FMNL2 HP
2 cardiovascular system MP:0005385 9.85 ADAM17 CCR6 CEACAM6 CEP43 HP IL12RB2
3 immune system MP:0005387 9.8 ADAM17 CCR6 CEACAM6 HP IL12RB2 IL18BP
4 hematopoietic system MP:0005397 9.44 ADAM17 CCR6 CEACAM6 CEP43 HP IL12RB2

Drugs & Therapeutics for Crohn's Disease

Drugs for Crohn's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
4
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
5
Prucalopride Approved Phase 4 179474-81-8 3052762
6
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
7
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
8
Phylloquinone Approved, Investigational Phase 4 84-80-0 5284607
9
Mercaptopurine Approved Phase 4 50-44-2 667490
10
Azithromycin Approved Phase 4 83905-01-5 447043
11
Risedronic acid Approved, Investigational Phase 4 105462-24-6 5245
12
Esketamine Approved, Investigational Phase 4 33643-46-8 182137
13
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
14
Golimumab Approved Phase 4 476181-74-5
15
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
16
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
19
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
20
Mesalazine Approved Phase 4 89-57-6 4075
21
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
22
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
23
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
24
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
25
L-Glutamine Approved, Investigational, Nutraceutical Phase 4 56-85-9 5961
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
27 Menaquinone Investigational Phase 4 1182-68-9
28 Cathartics Phase 4
29 Laxatives Phase 4
30 Hydrocortisone 17-butyrate 21-propionate Phase 4
31 Hepcidins Phase 4
32 Serotonin Receptor Agonists Phase 4
33 Epinephryl borate Phase 4
34 Diphosphonates Phase 4
35 Bronchodilator Agents Phase 4
36 Vitamin K Phase 4
37
Naphthoquinone Phase 4
38 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
39 Chrysarobin Phase 4
40 Antidepressive Agents Phase 4
41 calcium channel blockers Phase 4
42 Vitamin K 1 Phase 4
43 BB 1101 Phase 4
44 Vasoconstrictor Agents Phase 4
45 Adrenergic beta-Agonists Phase 4
46 Adrenergic alpha-Agonists Phase 4
47 Adrenergic Agonists Phase 4
48 Adrenergic Agents Phase 4
49 Mydriatics Phase 4
50 Sympathomimetics Phase 4

Interventional clinical trials:

(show top 50) (show all 1483)
# Name Status NCT ID Phase Drugs
1 The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial Unknown status NCT02704624 Phase 4
2 Can Vitamin D Supplementation in People With Crohn's Disease Improve Symptoms as an Adjunct Therapy? D-CODE Feasibility Randomised Controlled Trial Unknown status NCT03718182 Phase 4
3 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
4 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
5 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
6 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
7 Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy Unknown status NCT01024647 Phase 4
8 Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
9 Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
10 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
11 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
12 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
13 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
14 Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment Strategy Unknown status NCT02852694 Phase 4 Methotrexate;Adalimumab;Azathioprine / 6 Mercaptopurine
15 A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
16 Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China Unknown status NCT03901937 Phase 4 ω-3 polyunsaturated fatty acid
17 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
18 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Unknown status NCT03220841 Phase 4 Adalimumab Injection;Thiopurine
19 A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies Completed NCT00280956 Phase 4 natalizumab
20 A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease Completed NCT01183845 Phase 4
21 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
22 A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease Completed NCT01698307 Phase 4
23 Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study) Completed NCT02148718 Phase 4
24 Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease Completed NCT00546546 Phase 4 early immunosuppressants (azathioprine, methotrexate)
25 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial Completed NCT02256462 Phase 4 Adalimumab
26 An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications Completed NCT02764762 Phase 4 Vedolizumab;Adalimumab;Methotrexate
27 A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE) Completed NCT02630966 Phase 4 Vedolizumab;Placebo
28 Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease Completed NCT01947010 Phase 4
29 The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux Completed NCT00554710 Phase 4 infliximab+azathioprine;methylprednisolone or budesonide
30 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4 infliximab;placebo
31 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
32 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
33 A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone. Completed NCT01596894 Phase 4 Azithromycin + Metronidazole;Metronidazole
34 A Cluster Randomized Controlled Trial of a Treatment Algorithm for the Management of Crohn's Disease Completed NCT01030809 Phase 4
35 Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4 VSL#3
36 Modulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over Study Completed NCT02349594 Phase 4 Omegaven 10%;Intralipid 20%
37 Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease Completed NCT00588653 Phase 4
38 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
39 SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Completed NCT02199626 Phase 4
40 A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy Completed NCT02177071 Phase 4 INFLIXIMAB;AZATHIOPRINE;MERCAPTOPURINE;Methotrexate
41 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
42 The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study) Completed NCT01181765 Phase 4
43 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
44 A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease Completed NCT01442025 Phase 4 Infliximab
45 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study Completed NCT01817426 Phase 4 Infliximab
46 Vitamin D and Its Effects on Inflammation and Intestinal Permeability in Crohn's Disease in Remission Completed NCT01792388 Phase 4
47 Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab Completed NCT01556672 Phase 4 Adalimumab
48 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
49 Effects of Intraoperative Low-dose S-ketamine on Postoperative Mood and Pain in Patients With Crohn's Disease Undergoing Enterectomy With Mild to Moderate Depression: a Randomized Controlled Trial Completed NCT05506787 Phase 4 Esketamine;Placebo
50 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed NCT01804166 Phase 4 Infliximab;Golimumab

Search NIH Clinical Center for Crohn's Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


aminosalicylic acid
Azathioprine
Cholecalciferol
natalizumab
Opium
OPIUM ALKALOIDS HYDROCHLORIDE
OPIUM, POWDERED
paregoric
Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Crohn's Disease cell therapies at LifeMap Discovery.

Genetic Tests for Crohn's Disease

Anatomical Context for Crohn's Disease

Organs/tissues related to Crohn's Disease:

FMA: Intestine
MalaCards : Colon, Bone Marrow, Small Intestine, Skin, Bone, Placenta, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Crohn's Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Crohn's Disease

Articles related to Crohn's Disease:

(show top 50) (show all 35595)
# Title Authors PMID Year
1
Improving Food-Related Quality of Life in Inflammatory Bowel Disease through a Novel Web Resource: A Feasibility Randomised Controlled Trial. 62 41
36296976 2022
2
Serological profiling of Crohn's disease and ulcerative colitis patients reveals anti-microbial antibody signatures. 62 41
36157118 2022
3
Predicting outcomes for Crohn's disease using a molecular biomarker: profile trial. 62 41
36220241 2022
4
Citrate and hydroxycinnamate derivatives from Mume Fructus protect LPS-injured intestinal epithelial cells by regulating the FAK/PI3K/AKT signaling pathway. 62
36270558 2023
5
Low concentrations of Ambrosia maritima L. phenolic extract protect endothelial cells from oxidative cell death induced by H2O2 and sera from Crohn's disease patients. 62
36115603 2023
6
Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy. 62
36468568 2023
7
Development of a multimodal machine-learning fusion model to non-invasively assess ileal Crohn's disease endoscopic activity. 62
36375417 2022
8
[CROHN'S DISEASE. TO THE 90th ANNIVERSARY OF THE DESCRIPTION]. 62
36385092 2022
9
Painful fissured plaque in a girl with Crohn's disease. 62
36419801 2022
10
Principles for Assessing Quality of Life in Patients With Crohn's Disease. 62
36455221 2022
11
Cutaneous Mycobacterium marinum infection secondary to well water exposure masquerading as cutaneous Crohn's disease. 62
36457939 2022
12
Advanced imaging and Crohn's disease: An overview of clinical application and the added value of artificial intelligence. 62
36279627 2022
13
Pilot study of an elimination diet in adults with mild to moderate Crohn's disease. 62
36165053 2022
14
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study. 62
36457080 2022
15
Diagnostic accuracy of CT enterography correlated to histopathology in the diagnosis of small bowel Crohn's disease. 62
35000116 2022
16
Heterogeneity in pharmacological treatment and outcomes in Crohn's disease patients in Catalonia: a population-based observational study. 62
35499519 2022
17
Serum Monitoring of Recurrence in Post-Operative Crohn's Disease: Have We Arrived? 62
35737583 2022
18
Impact of Crohn's disease on obstetrical management. 62
36220540 2022
19
New magnetic resonance imaging sequences for fibrosis assessment in Crohn's disease: a pilot study. 62
36173349 2022
20
Escherichia coli bacteria associated with Crohn's disease persist within phagolysosomes. 62
36182819 2022
21
Endoscopic Balloon Dilation Is Cost-Effective for Crohn's Disease Strictures. 62
35290570 2022
22
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. 62
34628078 2022
23
Comparing Effectiveness of a Generic Oral Nutritional Supplement With Specialized Formula in the Treatment of Active Pediatric Crohn's Disease. 62
35259266 2022
24
Non-invasive Serological Monitoring for Crohn's Disease Postoperative Recurrence. 62
35689453 2022
25
Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease. 62
35212368 2022
26
Cross-Sectional Imaging May Serve a Greater Purpose in Postoperative Crohn's Disease. 62
35085827 2022
27
Crohn's Disease Patients Uniquely Contain Inflammatory Responses to Flagellin in a CD4 Effector Memory Subset. 62
35931421 2022
28
Segmental Versus Total Colectomy for Crohn's Disease in the Biologic Era: Results From The SCOTCH International, Multicentric Study. 62
35819368 2022
29
Unilateral vulval edema as the presenting cutaneous manifestation of Crohn's disease. 62
35844044 2022
30
Identification of potential predictive biomarkers and biological pathways and the correction with immune infiltration in the activation of Crohn's disease. 62
35861879 2022
31
Correction to: Surgical treatment of colonic Crohn's disease: a national snapshot study. 62
33651161 2022
32
Patient-Reported Impact of Symptoms in Crohn's Disease. 62
36375002 2022
33
Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn's disease patients. 62
35352625 2022
34
Granulomatous tracheo-bronchitis from Crohn's disease. 62
36382025 2022
35
Gastrocolic fistula in Crohn's disease: A case report and review of the literature. 62
36212753 2022
36
Intestinal fibrosis classification in patients with Crohn's disease using CT enterography-based deep learning: comparisons with radiomics and radiologists. 62
35616733 2022
37
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. 62
35895074 2022
38
Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. 62
34687970 2022
39
Crohn's disease and short bowel syndrome. 62
35767069 2022
40
The development of a minimum dataset for MRI reporting of anorectal fistula: a multi-disciplinary, expert consensus process. 62
35732929 2022
41
Histopathology of Pouch and Para-Pouch Inflammatory and Neoplastic Disorders. 62
35895870 2022
42
Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home. 62
33827316 2022
43
Gene/environment interaction in the susceptibility of Crohn's disease patients to aluminum. 62
35973536 2022
44
EBV-Positive Mucocutaneous Ulcer in Pediatric Crohn Disease-The Importance of Pathology. 62
35883235 2022
45
Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN. 62
36084231 2022
46
Single-balloon Enteroscopy for Evaluation of Small Bowel Crohn Disease Strictures: Peripheral Blood Lymphocytes As a Risk Factor for Strictures. 62
36468898 2022
47
Predictors of Perianal Fistula Healing in Children With Newly Diagnosed Crohn Disease. 62
36399175 2022
48
ATG16L1 WD40 domain-dependent IL10R (interleukin 10 receptor) signaling is insensitive to the T300A Crohn disease risk polymorphism. 62
35311452 2022
49
Food-Related Quality of Life in Children and Adolescents With Crohn's Disease. 62
35166341 2022
50
Drug-Related Adverse Events Necessitating Treatment Discontinuation in Pediatric Inflammatory Bowel Disease Patients. 62
36171635 2022

Variations for Crohn's Disease

ClinVar genetic disease variations for Crohn's Disease:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FMNL2 NM_052905.4(FMNL2):c.407T>C (p.Leu136Pro) SNV Likely Pathogenic
997783 rs1695370663 GRCh37: 2:153415301-153415301
GRCh38: 2:152558787-152558787
2 NOD2 NM_001370466.1(NOD2):c.*329_*334dup DUP Uncertain Significance
319479 rs886052047 GRCh37: 16:50766057-50766058
GRCh38: 16:50732146-50732147
3 NOD2 NM_001370466.1(NOD2):c.208A>G (p.Thr70Ala) SNV Uncertain Significance
1715769 GRCh37: 16:50733614-50733614
GRCh38: 16:50699703-50699703
4 NOD2 NM_001370466.1(NOD2):c.1608C>T (p.Tyr536=) SNV Likely Benign
319449 rs111608429 GRCh37: 16:50745511-50745511
GRCh38: 16:50711600-50711600
5 NOD2 NM_022162.3(NOD2):c.3019dup (p.Leu1007fs) DUP Likely Benign
4691 rs2066847 GRCh37: 16:50763778-50763779
GRCh38: 16:50729867-50729868
6 NOD2 NM_001370466.1(NOD2):c.-8-2340del DEL Likely Benign
319418 rs5743265 GRCh37: 16:50731059-50731059
GRCh38: 16:50697148-50697148
7 NOD2 NM_001370466.1(NOD2):c.1753G>T (p.Ala585Ser) SNV Likely Benign
319452 rs104895438 GRCh37: 16:50745656-50745656
GRCh38: 16:50711745-50711745
8 NOD2 NM_001370466.1(NOD2):c.2023C>T (p.Arg675Trp) SNV Not Provided
4693 rs2066844 GRCh37: 16:50745926-50745926
GRCh38: 16:50712015-50712015

Copy number variations for Crohn's Disease from CNVD:

6 (show all 25)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19625 1 150839831 150840116 Deletion and duplication LCE3C Crohn''s disease
2 19631 1 150852910 150853198 Deletion and duplication LCE3B Crohn''s disease
3 71426 12 69818942 132349534 Copy number Crohn''s disease
4 112709 17 40930407 78774742 Copy number Crohn''s disease
5 139336 2 179004449 242951149 Copy number Crohn''s disease
6 194979 5 147200000 152100000 Low copy numbers IRGM Crohn''s disease
7 195288 5 149800000 152700000 Copy number Crohn''s disease
8 195354 5 150157836 180857866 Copy number Crohn''s disease
9 195374 5 150183562 180857866 Copy number Crohn''s disease
10 195384 5 150207878 150208422 Deletion IRGM Crohn''s disease
11 195385 5 150207878 150208422 Deletion and duplication IRGM Crohn''s disease
12 210788 6 31416574 170899992 Copy number Crohn''s disease
13 211338 6 32582950 170899992 Copy number Crohn''s disease
14 211384 6 32609209 170899992 Copy number Crohn''s disease
15 211736 6 336751 356443 Copy number IRF4 Crohn''s disease
16 230702 8 1 12700000 Copy number Crohn''s disease
17 241420 8 6200000 12700000 Copy number DEFB4A Crohn''s disease
18 241431 8 6200000 12700000 Duplication DEFB103A Crohn''s disease
19 241433 8 6200000 12700000 Duplication DEFB4A Crohn''s disease
20 241436 8 6200000 12700000 Duplication SPAG11B Crohn''s disease
21 241467 8 6200000 12700000 Low copy numbers Crohn''s disease
22 242030 8 6873390 6875823 Copy number Crohn''s disease
23 242532 8 7259842 7791647 Copy number DEFB4A Crohn''s disease
24 242534 8 7259842 7791647 Deletion and duplication DEFB4A Crohn''s disease
25 242535 8 7259842 7791647 Deletion and duplication DEFB4A Crohn''s disease

Expression for Crohn's Disease

LifeMap Discovery
Genes differentially expressed in tissues of Crohn's Disease patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 REG1A regenerating family member 1 alpha Colon + 4.42 0.002
2 CXCL2 C-X-C motif chemokine ligand 2 Colon + 4.02 0.000
3 REG1B regenerating family member 1 beta Colon + 3.99 0.008
4 LCN2 lipocalin 2 Colon + 3.90 0.000
5 REG3A regenerating family member 3 alpha Colon + 3.74 0.026
6 CXCL11 C-X-C motif chemokine ligand 11 Colon + 3.70 0.016
7 CXCL1 C-X-C motif chemokine ligand 1 Colon + 3.60 0.000
8 CXCL8 C-X-C motif chemokine ligand 8 Colon + 3.50 0.004
9 DEFA6 defensin alpha 6 Colon + 3.49 0.029
10 S100A8 S100 calcium binding protein A8 Colon + 3.04 0.017
Search GEO for disease gene expression data for Crohn's Disease.

Pathways for Crohn's Disease

Pathways related to Crohn's Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.02 UBE4A S100A9 S100A8 S100A12 ITGA4 INPP5D
2
Show member pathways
12.58 S100A12 INPP5D IL26 IL18RAP IL18BP IL12RB2
3 11.23 ITGA4 IL12RB2 CCR6
4 10.64 S100A9 S100A8

GO Terms for Crohn's Disease

Biological processes related to Crohn's Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.18 S100A9 S100A8 S100A12 LACC1 IRGM IL18RAP
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.13 S100A9 S100A8 S100A12 IL18RAP
3 defense response to bacterium GO:0042742 10.07 HP IRGM S100A12 S100A8 S100A9
4 defense response to fungus GO:0050832 9.93 S100A12 S100A8 S100A9
5 positive regulation of cell growth GO:0030307 9.92 S100A9 S100A8 CEP43 ADAM17
6 nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070431 9.84 LACC1 IRGM
7 chronic inflammatory response GO:0002544 9.81 S100A9 S100A8
8 autocrine signaling GO:0035425 9.8 S100A9 S100A8
9 peptidyl-cysteine S-nitrosylation GO:0018119 9.78 S100A9 S100A8
10 immune system process GO:0002376 9.76 HP INPP5D IRGM LACC1 S100A12 S100A8
11 sequestering of zinc ion GO:0032119 9.73 S100A9 S100A8
12 response to lipopolysaccharide GO:0032496 9.65 S100A9 S100A8 IL18BP IL12RB2 ADAM17
13 neutrophil aggregation GO:0070488 9.56 S100A9 S100A8
14 leukocyte migration involved in inflammatory response GO:0002523 9.1 S100A9 S100A8 CCR6

Molecular functions related to Crohn's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 arachidonic acid binding GO:0050544 9.46 S100A9 S100A8
2 Toll-like receptor 4 binding GO:0035662 9.26 S100A9 S100A8
3 RAGE receptor binding GO:0050786 9.1 S100A9 S100A8 S100A12

Sources for Crohn's Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....